Use of Evidence-based Practices in Alcoholism Treatment

在酗酒治疗中使用循证实践

基本信息

批准号：
8299987
负责人：
Paul M Roman
金额：
$ 57.18万
依托单位：
UNIVERSITY OF GEORGIA
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-07-10 至 2014-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8299987
关键词：
Accreditation Address Administrator Adopted Adoption Affect Alcohol dependence Area Attitude Behavior Behavior Therapy Behavioral Belief Campral Caring Characteristics Client Clinical Clinical Research Clinical Trials Clinical Trials Network Communication Counseling Coupled Data Data Collection Development Diffuse Diffusion Disincentive Economic Factors Economics Environment Environmental Risk Factor Evidence based practice Evidence based treatment Exposure to Familiarity Funding Funding Agency Future Goals Grant Hand Health Personnel Health Services Research Incentives Injectable Interview Licensure Longitudinal Studies Marketing Measures Medicaid Medical Methods Modality Monitor Naltrexone Organization administrative structures Patients Pharmaceutical Preparations Pharmacological Treatment Pharmacotherapy Philosophy Policies Private Sector Process Professional counselor Program Reviews Questionnaires Regulation Relative (related person)Research Research Personnel Resources Sampling Services Site Source Structure Techniques Technology Time Training Translations United States National Institutes of Health United States Substance Abuse and Mental Health Services Administration acamprosate addiction alcohol abuse therapy alcoholism therapy base community based treatment comparative contingency management cost effectiveness measure evidence base innovation medication compliance motivational enhancement therapy programs psychosocial research to practice sound substance abuse treatment therapy design treatment center treatment organization treatment program treatment strategy trend

项目摘要

DESCRIPTION (provided by applicant): Recent FDA approval of acamprosate (Campral(r)) and long-acting injectable naltrexone (Vivitrol(r)) has given alcohol treatment providers and their patients' new treatment options in addition to existing pharmacotherapies and psychosocial counseling techniques for the treatment of alcohol dependence. In addition, the evidence base continues to accumulate for a number of counseling techniques such as motivational interviewing and contingency management, and manualized approaches are being developed and disseminated. Coupled with these developments in treatment "technologies" is an ever-increasing emphasis by states and payers on the use of evidence-based practices. Together, these factors are beginning to influence changes in the content of treatment services. However, there remain significant concerns about the effective dissemination of these evidence-based treatment techniques and the elimination of the "research to practice gap" that characterizes much of the addiction treatment field. There are few mechanisms to measure the effectiveness of various dissemination strategies, the extent of adoption of evidence-based innovations, and the fidelity with which those techniques are implemented in diverse, real-world treatment settings. Moreover, there is scant research on the organizational, staffing, and environmental factors that facilitate or impede the diffusion, adoption, and implementation of evidence-based behavioral and pharmacological approaches to alcoholism treatment. The economic disincentives to integrating new practices in treatment organizations and counselor repertoires likewise require study. To address these needs, we propose a longitudinal data collection effort with N=400 alcohol treatment centers from which related data were collected in 2001-2006. Longitudinal data in hand provide a valuable baseline against which to monitor future adoption behaviors of existing techniques, diffusion of emerging treatment innovations, and discontinuation of previously-used methods. Because the baseline data include a period of time before the approval of acamprosate and Vivitrol, this study would offer a unique opportunity to monitor past, present, and future adoption of these medications specifically, and related treatment strategies more generally.

描述（由申请人提供）：最近的FDA批准了Acamprosate（Campral（r））和长效注射纳曲酮（Vivitrol（R）），除了现有的药物治疗和心理社会咨询技术以治疗酒精依赖性的治疗方法外，还给予了酒精治疗提供者及其患者的新治疗方案。此外，证据基础继续积累了许多咨询技术，例如动机访谈和应急管理，并且正在开发和传播手动化方法。再加上“技术”治疗中的这些发展，是各州和付款人对使用基于证据的实践的强调。这些因素共同开始影响治疗服务内容的变化。但是，人们对这些基于证据的治疗技术的有效传播以及消除了许多成瘾治疗领域的“研究差距”的有效传播。衡量各种传播策略的有效性，采用循证创新的程度以及这些技术在多样化的现实世界治疗环境中实施的忠诚度。此外，关于组织，人员配备和环境因素的研究很少，这些因素促进或阻碍了基于循证的行为和药理学方法的酗酒治疗的传播，采用和实施。在治疗组织和辅导员曲目中融合新实践的经济障碍同样需要研究。为了满足这些需求，我们提出了纵向数据收集工作，其中n = 400个酒精处理中心，从2001 - 2006年收集了相关数据。手头的纵向数据提供了一个有价值的基准，可以监测现有技术的未来采用行为，新兴治疗创新的扩散以及以前使用的方法的中断。由于基线数据包括在批准分娩酸盐和Vivitrol之前的一段时间，因此这项研究将提供一个独特的机会来监测这些药物的过去，现在和将来的专门采用，并更广泛地使用相关的治疗策略。